T1 high-grade bladder carcinoma outcome

the role of p16, topoisomerase-IIα, survivin, and E-cadherin

Maria Rosaria Raspollini, Rafael J. Luque, Carmen Luz Menendez, Enrico Bollito, Matteo Brunelli, Guido Martignoni, Rodolfo Montironi, Liang Cheng, Ana Blanca, Gianna Baroni, Andrea Minervini, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalHuman Pathology
Volume57
DOIs
StatePublished - Nov 1 2016

Fingerprint

Type II DNA Topoisomerase
Cadherins
Urinary Bladder
Biomarkers
Carcinoma
Disease-Free Survival
Galectin 3
Validation Studies
Papillary Carcinoma
Mycobacterium bovis
Connective Tissue
Therapeutics
Survival
Research
Neoplasms

Keywords

  • Bladder cancer
  • E-cadherin
  • p16
  • Progression
  • Survivin
  • T1
  • Topoisomerase-IIα

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Raspollini, M. R., Luque, R. J., Menendez, C. L., Bollito, E., Brunelli, M., Martignoni, G., ... Lopez-Beltran, A. (2016). T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin. Human Pathology, 57, 78-84. https://doi.org/10.1016/j.humpath.2016.06.022

T1 high-grade bladder carcinoma outcome : the role of p16, topoisomerase-IIα, survivin, and E-cadherin. / Raspollini, Maria Rosaria; Luque, Rafael J.; Menendez, Carmen Luz; Bollito, Enrico; Brunelli, Matteo; Martignoni, Guido; Montironi, Rodolfo; Cheng, Liang; Blanca, Ana; Baroni, Gianna; Minervini, Andrea; Lopez-Beltran, Antonio.

In: Human Pathology, Vol. 57, 01.11.2016, p. 78-84.

Research output: Contribution to journalArticle

Raspollini, MR, Luque, RJ, Menendez, CL, Bollito, E, Brunelli, M, Martignoni, G, Montironi, R, Cheng, L, Blanca, A, Baroni, G, Minervini, A & Lopez-Beltran, A 2016, 'T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin', Human Pathology, vol. 57, pp. 78-84. https://doi.org/10.1016/j.humpath.2016.06.022
Raspollini, Maria Rosaria ; Luque, Rafael J. ; Menendez, Carmen Luz ; Bollito, Enrico ; Brunelli, Matteo ; Martignoni, Guido ; Montironi, Rodolfo ; Cheng, Liang ; Blanca, Ana ; Baroni, Gianna ; Minervini, Andrea ; Lopez-Beltran, Antonio. / T1 high-grade bladder carcinoma outcome : the role of p16, topoisomerase-IIα, survivin, and E-cadherin. In: Human Pathology. 2016 ; Vol. 57. pp. 78-84.
@article{ed2b3c1ffbca4b9099b914721fa4bcb6,
title = "T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin",
abstract = "High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.",
keywords = "Bladder cancer, E-cadherin, p16, Progression, Survivin, T1, Topoisomerase-IIα",
author = "Raspollini, {Maria Rosaria} and Luque, {Rafael J.} and Menendez, {Carmen Luz} and Enrico Bollito and Matteo Brunelli and Guido Martignoni and Rodolfo Montironi and Liang Cheng and Ana Blanca and Gianna Baroni and Andrea Minervini and Antonio Lopez-Beltran",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.humpath.2016.06.022",
language = "English (US)",
volume = "57",
pages = "78--84",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - T1 high-grade bladder carcinoma outcome

T2 - the role of p16, topoisomerase-IIα, survivin, and E-cadherin

AU - Raspollini, Maria Rosaria

AU - Luque, Rafael J.

AU - Menendez, Carmen Luz

AU - Bollito, Enrico

AU - Brunelli, Matteo

AU - Martignoni, Guido

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Blanca, Ana

AU - Baroni, Gianna

AU - Minervini, Andrea

AU - Lopez-Beltran, Antonio

PY - 2016/11/1

Y1 - 2016/11/1

N2 - High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.

AB - High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.

KW - Bladder cancer

KW - E-cadherin

KW - p16

KW - Progression

KW - Survivin

KW - T1

KW - Topoisomerase-IIα

UR - http://www.scopus.com/inward/record.url?scp=84984806993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984806993&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.06.022

DO - 10.1016/j.humpath.2016.06.022

M3 - Article

VL - 57

SP - 78

EP - 84

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -